AMBEA Stock Analysis: Ambea | ST
Medical Care Facilities | ST, Sweden | Market Cap: 12.588m SEK | 12M Return: 20.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.0M
EPS Trend: 93.4%
Qual. Beats: 0
Rev. Trend: 97.6%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 9.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ambea AB is a Nordic health care services provider operating in Sweden, Norway, and Denmark. The company delivers elderly care, disability care, and psychosocial support services through multiple branded segments, including Vardaga (nursing homes and home care for the elderly), Nytida (social care and schools for children with neuropsychiatric disorders), Stendi (personal assistance and social care), Altiden (disability and home care), Klara (staff solutions for social welfare services), Lära (training and coaching), and Validia (residential and rehabilitation services).
The company is headquartered in Solna, Sweden, was incorporated in 1993, and originally operated under the name H-Careholding AB before adopting its current name in September 2007. As a participant in the Health Care Facilities sub-industry, Ambea operates in a regulated sector where care services are typically procured or funded through public welfare systems in the Nordic region.
- Sweden elderly care pricing renegotiation pressures Vardaga margins
- Rising staff costs across Nordic operations squeeze profitability
- M&A pipeline and demographic tailwinds support long-term segment growth
| Net Income: 712.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -0.48 > 1.0 |
| NWC/Revenue: -14.82% < 20% (prev -16.89%; Δ 2.08% < -1%) |
| CFO/TA 0.10 > 3% & CFO 2.10b > Net Income 712.0m |
| Net Debt (22.7b) to EBITDA (3.00b): 7.55 < 3 |
| Current Ratio: 0.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (81.7m) vs 12m ago -2.35% < -2% |
| Gross Margin: 53.15% > 18% (prev 57.85%; Δ -4.70% > 0.5%) |
| Asset Turnover: 84.48% > 50% (prev 78.20%; Δ 6.28% > 0%) |
| Interest Coverage Ratio: 2.54 > 6 (EBIT TTM 1.44b / Interest Expense TTM 568.0m) |
| A: -0.12 (Total Current Assets 2.00b - Total Current Liabilities 4.46b) / Total Assets 21.0b |
| B: -0.05 (Retained Earnings -1.02b / Total Assets 21.0b) |
| C: 0.07 (EBIT TTM 1.44b / Avg Total Assets 19.7b) |
| D: 0.33 (Book Value of Equity 5.17b / Total Liabilities 15.8b) |
| Altman-Z'' = -0.09 = B |
| DSRI: 0.78 (Receivables 1.64b/1.82b, Revenue 16.6b/14.4b) |
| GMI: 1.09 (GM 57.85% / 53.15%) |
| AQI: 1.05 (AQ_t 0.44 / AQ_t-1 0.42) |
| SGI: 1.16 (Revenue 16.6b / 14.4b) |
| TATA: -0.07 (NI 712.0m - CFO 2.10b) / TA 21.0b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at SEK 142.60 with a total of 71,901 shares traded. Over the past week, the price has changed by -8.94%, over one month by +1.57%, over three months by +6.00% and over the past year by +20.71%.
Current recommended Stop Loss: 135.90 (which is 4.7% or 1.3 ATR below the current price).
Ambea has no consensus analysts rating.
P/E Trailing = 18.3158
P/S = 0.7546
P/B = 2.348
Revenue TTM = 16.6b SEK
EBIT TTM = 1.44b SEK
EBITDA TTM = 3.00b SEK
Long Term Debt = 2.61b SEK (from longTermDebt, last quarter)
Short Term Debt = 2.36b SEK (from shortTermDebt, last quarter)
Debt = 22.8b SEK (from shortLongTermDebtTotal, last quarter) + Leases 9.49b
Net Debt = 22.7b SEK (calculated: Debt 22.8b - CCE 173.0m)
Enterprise Value = 35.3b SEK (12.6b + Debt 22.8b - CCE 173.0m)
Interest Coverage Ratio = 2.54 (Ebit TTM 1.44b / Interest Expense TTM 568.0m)
EV/FCF = 17.96x (Enterprise Value 35.3b / FCF TTM 1.96b)
FCF Yield = 5.57% (FCF TTM 1.96b / Enterprise Value 35.3b)
FCF Margin = 11.82% (FCF TTM 1.96b / Revenue TTM 16.6b)
Net Margin = 4.29% (Net Income TTM 712.0m / Revenue TTM 16.6b)
Gross Margin = 53.15% ((Revenue TTM 16.6b - Cost of Revenue TTM 7.78b) / Revenue TTM)
Gross Margin QoQ = 7.77% (prev none%)
Tobins Q-Ratio = 1.68 (Enterprise Value 35.3b / Total Assets 21.0b)
Interest Expense / Debt = 2.49% (Interest Expense 568.0m / Debt 22.8b)
Taxrate = 22.69% (209.0m / 921.0m)
NOPAT = 1.11b (EBIT 1.44b * (1 - 22.69%))
Current Ratio = 0.45 (Total Current Assets 2.00b / Total Current Liabilities 4.46b)
Debt / Equity = 4.42 (Debt 22.8b / totalStockholderEquity, last quarter 5.17b)
Debt / EBITDA = 7.55 (Net Debt 22.7b / EBITDA 3.00b)
Debt / FCF = 11.55 (Net Debt 22.7b / FCF TTM 1.96b)
Total Stockholder Equity = 5.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.62% (Net Income 712.0m / Total Assets 21.0b)
RoE = 13.73% (Net Income TTM 712.0m / Total Stockholder Equity 5.19b)
RoCE = 18.47% (EBIT 1.44b / Capital Employed (Equity 5.19b + L.T.Debt 2.61b))
RoIC = 5.96% (NOPAT 1.11b / Invested Capital 18.7b)
WACC = 3.69% (E(12.6b)/V(35.4b) * Re(6.89%) + D(22.8b)/V(35.4b) * Rd(2.49%) * (1-Tc(0.23)))
Discount Rate = 6.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -77.78 | Cagr: -4.01%
[DCF] Terminal Value 76.52% ; FCFF base≈1.90b ; Y1≈2.05b ; Y5≈2.49b
[DCF] Fair Price = 193.5 (EV 38.2b - Net Debt 22.7b = Equity 15.6b / Shares 80.4m; r=8.35% [WACC [floored]]; 5y FCF grow 8.75% → 2.50% )
EPS Correlation: 93.40 | EPS CAGR: 35.03% | SUE: 0.53 | # QB: 0
Revenue Correlation: 97.65 | Revenue CAGR: 9.08% | SUE: 0.98 | # QB: 2
EPS current Quarter (2026-06-30): EPS=1.81 | Chg30d=+5.52% | Revisions=+0% | Analysts=2
EPS next Quarter (2026-09-30): EPS=4.34 | Chg30d=+5.08% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=10.34 | Chg30d=-4.99% | Revisions=+50% | GrowthEPS=+30.6% | GrowthRev=+8.2%
EPS next Year (2027-12-31): EPS=11.81 | Chg30d=-3.28% | Revisions=+50% | GrowthEPS=+14.2% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: +67% (up=6, down=0)